• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment, and follow-up.

作者信息

d'Amore Francesco, Federico Massimo, de Leval Laurence, Ellin Fredrik, Hermine Olivier, Kim Won Seog, Lemonnier François, Vermaat Joost S P, Wulf Gerald, Buske Christian, Dreyling Martin, Jerkeman Mats

机构信息

Department of Haematology Aarhus University Hospital Aarhus Denmark.

Department of Clinical Medicine Aarhus University Hospital Aarhus Denmark.

出版信息

Hemasphere. 2025 May 7;9(5):e70128. doi: 10.1002/hem3.70128. eCollection 2025 May.

DOI:10.1002/hem3.70128
PMID:40342876
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12059256/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79de/12059256/15af573b4946/HEM3-9-e70128-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79de/12059256/91f1db8846f8/HEM3-9-e70128-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79de/12059256/4f4c557a89e9/HEM3-9-e70128-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79de/12059256/ce2466016c82/HEM3-9-e70128-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79de/12059256/edb37240f151/HEM3-9-e70128-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79de/12059256/3bd6528c4a5c/HEM3-9-e70128-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79de/12059256/15af573b4946/HEM3-9-e70128-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79de/12059256/91f1db8846f8/HEM3-9-e70128-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79de/12059256/4f4c557a89e9/HEM3-9-e70128-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79de/12059256/ce2466016c82/HEM3-9-e70128-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79de/12059256/edb37240f151/HEM3-9-e70128-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79de/12059256/3bd6528c4a5c/HEM3-9-e70128-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79de/12059256/15af573b4946/HEM3-9-e70128-g005.jpg

相似文献

1
Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment, and follow-up.外周T细胞和自然杀伤细胞淋巴瘤：ESMO-EHA诊断、治疗及随访临床实践指南
Hemasphere. 2025 May 7;9(5):e70128. doi: 10.1002/hem3.70128. eCollection 2025 May.
2
Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment and follow-up.外周T细胞和自然杀伤细胞淋巴瘤：ESMO-EHA诊断、治疗及随访临床实践指南
Ann Oncol. 2025 Jun;36(6):626-644. doi: 10.1016/j.annonc.2025.01.023. Epub 2025 May 8.
3
Human immunodeficiency virus-associated Lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.人类免疫缺陷病毒相关淋巴瘤：EHA-ESMO诊断、治疗及随访临床实践指南
Hemasphere. 2024 Sep 3;8(9):e150. doi: 10.1002/hem3.150. eCollection 2024 Sep.
4
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.原发性中枢神经系统淋巴瘤：欧洲血液学协会-欧洲肿瘤内科学会诊断、治疗及随访临床实践指南
Ann Oncol. 2024 May 14. doi: 10.1016/j.annonc.2023.11.010.
5
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.原发性中枢神经系统淋巴瘤：EHA-ESMO诊断、治疗及随访临床实践指南
Hemasphere. 2024 Jun 4;8(6):e89. doi: 10.1002/hem3.89. eCollection 2024 Jun.
6
Human immunodeficiency virus-associated lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.人类免疫缺陷病毒相关淋巴瘤：EHA-ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2024 Oct;35(10):840-859. doi: 10.1016/j.annonc.2024.06.003. Epub 2024 Sep 3.
7
Correction to "Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up".《原发性中枢神经系统淋巴瘤：EHA-ESMO诊断、治疗及随访临床实践指南》勘误
Hemasphere. 2024 Jul 22;8(7):e118. doi: 10.1002/hem3.118. eCollection 2024 Jul.
8
EHA Endorsement of ESMO Clinical Practice Guidelines for Marginal Zone Lymphomas.欧洲血液学协会（EHA）对欧洲肿瘤内科学会（ESMO）边缘区淋巴瘤临床实践指南的认可。
Hemasphere. 2020 Mar 11;4(2):e351. doi: 10.1097/HS9.0000000000000351. eCollection 2020 Apr.
9
Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.外周T细胞淋巴瘤：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2015 Sep;26 Suppl 5:v108-15. doi: 10.1093/annonc/mdv201.
10
Angiocentric lymphomas (lymphomatous vasculitis).血管中心性淋巴瘤（淋巴瘤性血管炎）
Semin Diagn Pathol. 2001 Feb;18(1):67-77.

本文引用的文献

1
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study.本妥昔单抗维迪辛联合环磷酰胺、多柔比星、依托泊苷和泼尼松治疗 CD30 阳性外周 T 细胞淋巴瘤：一项多中心、单臂、2 期研究。
Lancet Haematol. 2024 Sep;11(9):e671-e681. doi: 10.1016/S2352-3026(24)00171-6. Epub 2024 Jul 24.
2
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.口服阿扎胞苷与滤泡辅助 T 细胞淋巴瘤（ORACLE）患者标准治疗的比较：一项开放标签随机 3 期研究。
Lancet Haematol. 2024 Jun;11(6):e406-e414. doi: 10.1016/S2352-3026(24)00102-9.
3
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry.复发外周 T 细胞淋巴瘤的治疗策略和结果：荷兰癌症登记处的结果。
Blood Adv. 2024 Jul 23;8(14):3619-3628. doi: 10.1182/bloodadvances.2023012531.
4
A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas.一种实用的方法，用于现代 T 细胞和 NK 细胞淋巴瘤的诊断和分类。
Blood. 2024 Oct 31;144(18):1855-1872. doi: 10.1182/blood.2023021786.
5
Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia.芦可替尼治疗复发/难治性大颗粒淋巴细胞白血病的疗效。
Br J Haematol. 2024 Sep;205(3):915-923. doi: 10.1111/bjh.19476. Epub 2024 Apr 19.
6
First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial.一线信迪利单抗联合培门冬酶、吉西他滨和奥沙利铂治疗晚期结外自然杀伤/T细胞淋巴瘤（SPIRIT）：一项多中心、单臂、2期试验
Lancet Haematol. 2024 May;11(5):e336-e344. doi: 10.1016/S2352-3026(24)00066-8. Epub 2024 Mar 27.
7
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.罗米地辛联合环磷酰胺、多柔比星、长春新碱和泼尼松与环磷酰胺、多柔比星、长春新碱和泼尼松治疗未经治疗的外周 T 细胞淋巴瘤患者：Ro-CHOP 试验的最终分析。
J Clin Oncol. 2024 May 10;42(14):1612-1618. doi: 10.1200/JCO.23.01687. Epub 2024 Feb 16.
8
Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands.一线治疗 I(E)期外周 T 细胞淋巴瘤的联合治疗模式的结果；来自荷兰的全国性基于人群的队列研究。
Haematologica. 2024 Apr 1;109(4):1163-1170. doi: 10.3324/haematol.2023.283174.
9
Follicular helper T-cell lymphomas: disease spectrum, relationship with clonal hematopoiesis, and mimics. A report of the 2022 EA4HP/SH lymphoma workshop.滤泡辅助性 T 细胞淋巴瘤：疾病谱、与克隆性造血的关系及类似物。2022 年 EA4HP/SH 淋巴瘤研讨会报告。
Virchows Arch. 2023 Sep;483(3):349-365. doi: 10.1007/s00428-023-03607-5. Epub 2023 Jul 27.
10
Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation.接受干细胞移植的 T 细胞淋巴瘤患者长期生存的真实世界数据。
Blood Cancer J. 2023 Jun 26;13(1):95. doi: 10.1038/s41408-023-00868-w.